ATX-101, an injectable drug being studied for the reduction of localized fat is a proprietary formulation of deoxycholate, an endogenous compound that is present in the body to promote the natural breakdown of dietary fat.
The patent application is titled ‘Formulations of Deoxycholic Acid and Salts Thereof.’
Kythera president and CEO Keith Leonard said the move was a key addition to their existing patent portfolio and would enforce their development efforts of ATX-101.
"We are focused on building on our strong patent protection as we further investigate the long-term safety and efficacy profile of ATX-101," Leonard added.